High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom

US12060425B2 · kind B2 · utility

Assignee

• SHANGHAI EPIMAB BIOTHERAPEUTICS CO., LTD. · CN

Inventors

• Xuan Wu · Longbeilingcun, CN
• Shiyong GONG · Shanghai, CN
• Chengbin Wu · Shanghai, CN

Key dates

• Filing date: Apr 30, 2019
• Grant date: Aug 13, 2024
• Expiry date: Feb 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

High-affinity antibodies recognizing Programmed Death Ligand-1 (PD-1) and Lymphocyte Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 and anti-LAG-3 antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both PD-1 and LAG-3 simultaneously. Such bispecific FIT-Ig binding proteins are useful for treatment of cancer.